The Neuroscience Biomarker Program is dedicated to advancing biomarkers for neurological disease. The program is focused on supporting research to promote biomarkers that will improve the quality and efficiency of Phase II clinical trials and clinical practice. The NINDS Biomarker Program provides support for biomarker and endpoint discovery, along with analytical and clinical validation in a manner that is consistent with FDA guidelines.

An interactive Q&A webinar was held for interested applicants on Thursday November 10, 2022 at 2:00 PM ET. All investigators who are interested in learning about the NINDS Biomarker funding opportunities are encouraged to participate. Investigators can find information about these funding opportunities at:


PAR-22-089: Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
PAR-21-056: Analytical Validation of a Candidate Biomarker for Neurological Disease (U01) (Clinical Trial Optional)
PAR-21-057: Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)
PAR-21-058: Clinical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional)
PAR-21-059: Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)


Next Receipt date for all NINDS Biomarker Funding Opportunities is February 22, 2023.

свернуть